Business
QuidelOrtho Corporation Announces Secondary Offering of Common Stock by the Carlyle Group
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics
About this update from Quidelortho Corporation
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nQuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today the launch of an underwritten secondary offering (the “Offering”) by Carlyle Partners VI Cayman Holdings, L.P. (the “Selling Stockholder”) of 8,260,183 shares of the Company’s common stock (“Common Stock”).\n\n\nThe Selling Stockholder will receive all of the proceeds from the Offering. The Company is not selling any shares of Common Stock in the Offering and will not receive any proceeds from the Offering.\n\n\nThe last reported sale price of QuidelOrtho’s Common Stock on November 19, 2024 was $38.58 per share. Goldman Sachs & Co. LLC is acting as the sole underwriter of the Offering.\n\n\nThe underwriter proposes to offer the shares of Common Stock to the public at a fixed price, which may be changed at any time without notice.\n\n\nFollowing the Offering, the Selling Stockholder will not beneficially own any shares of QuidelOrtho’s Common Stock, other than de minimis amounts held or owned from time to time in the ordinary course of business. As a result, QuidelOrtho’s Principal Stockholders Agreement with the Selling Stockholder will terminate pursuant to its terms and the Selling Stockholder will no longer have the right to nominate members to QuidelOrtho’s Board of Directors in accordance with the terms of the Principal Stockholders Agreement.\n\n\nThe Offering is being made pursuant to an effective shelf registration statement (including a prospectus) filed by the Company with the U.S. Securities and Exchange Commission (“SEC”) to which this communication relates. Before you invest, you should read the prospectus in the shelf registration statement and other documents the Company has filed with the SEC for more complete information about the Company and the Offering. The Offering will be made only by means of a free writing prospectus, a prospectus and a related prospectus supplement relating to the Offering, copies of which may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY, 10282, phone number: (866) 471-2526, or by email at [email protected]. A copy of the free writing prospectus, the prospec...